CARA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.8052 USD | +5.96% |
|
+5.93% | +8.37% |
| 05-13 | Earnings Flash (CARA) CARA THERAPEUTICS Posts Q1 Revenue $2.1M, vs. Street Est of $1.7M | MT |
| 05-13 | Cara Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Presentation Operator MessageOperator (Operator)Good morning, and welcome to the Cara Therapeu...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Cara Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company is focused on treatment paradigm to improve the lives of patients suffering from chronic pruritus. It is developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated with Notalgia Paresthetica (NP), a common, underdiagnosed neuropathy affecting the upper back. It is conducting Phase II/III Clinical Program in NP. The program is comprised of two studies - KOURAGE 1 and KOURAGE 2, which are double-blind, placebo-controlled, eight-week studies with patients allowed to roll-over into open-label 52-week extensions. It has developed an IV formulation of difelikefalin, for the treatment of moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis. The IV formulation is out-licensed worldwide.
Sector
Pharmaceuticals
Calendar
2024-06-04
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
0.8052
USD
Average target price
5.12
USD
Spread / Average Target
+535.87%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +8.37% | 44.03M | |
| -2.32% | 92.59B | |
| +3.16% | 41.43B | |
| -11.10% | 33.49B | |
| +53.61% | 25.06B | |
| -9.41% | 12.77B | |
| -12.25% | 11.58B | |
| -44.00% | 11.35B | |
| +5.92% | 8.97B | |
| -6.32% | 8.3B |
- Stock Market
- Equities
- CARA Stock
- News Cara Therapeutics, Inc.
- Transcript : Cara Therapeutics, Inc. - Special Call
